Triple-negative breast cancer (TNBC) lacks ER and HER2 expression, and treatment primarily relies on chemotherapy; however, PARP inhibition can be used to exploit synthetic lethality in tumours with breast cancer susceptibility gene 1/2 (BRCA1/2) mutations [6]. This evidence concerns the gene ERBB2 and neoplasm.